SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1473-1478. Prepublished online as a Blood First Edition Paper on May 3, 2005; DOI 10.1182/blood-2004-12-4689. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-12-4689v1 106/4/1473    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lavoie, J. C. Articles by Nevill, T. J. Search for Related Content PubMed PubMed Citation Articles by Lavoie, J. C. Articles by Nevill, T. J. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver Julye C. Lavoie, Joseph M. Connors, Gordon L. Phillips, Donna E. Reece, Michael J. Barnett, Donna L. Forrest, Randy D. Gascoyne, Donna E. Hogge, Stephen H. Nantel, John D. Shepherd, Clayton A. Smith, Kevin W. Song, Heather J. Sutherland, Cynthia L. Toze, Nicholas J. S. Voss, and Thomas J. Nevill From the Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada; the Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; the Department of Pathology and Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; and the University of British Columbia, Vancouver, BC, Canada. Beginning in 1985, patients in British Columbia with Hodgkin lymphoma (HL) that was not controlled by conventional chemotherapy routinely underwent high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT). Long-term complications of HD-ASCT have become apparent as more patients survive without recurrence of HL. Data were obtained retrospectively on the first 100 patients that underwent HD-ASCT for HL in Vancouver, focusing on relapse, treatment-related complications, and the occurrence of late events. Fifty-three patients remain alive (median follow-up, 11.4 years [range, 10.0-17.4 years]) with an overall survival (OAS) of 54% at 15 years. OAS was significantly better in patients in first relapse (67%) than in patients with primary refractory-induction failure (39%) and advanced disease (29%) (P = .002). The major cause of death was progression of HL (32% at 15 years). Treatment-related mortality, including death from second malignancy, was 17% at 15 years. Cumulative risk of a second malignancy was 9% at 15 years. Karnofsky performance status was at least 90% in 47 patients although hypogonadism (20 patients), hypothyroidism (12 patients), unusual infections (10 patients), anxiety or depression (7 patients), and cardiac disease (5 patients) were not uncommon in survivors. HD-ASCT can lead to durable remissions in relapsed or refractory HL with acceptable but definite late toxicity. The occurrence of late events necessitates lifelong medical surveillance. (Blood. 2005;106:1473-1478) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF] P. D. Cole, C. L. Schwartz, R. A. Drachtman, P. A. de Alarcon, L. Chen, and T. M. Trippett Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report J. Clin. Oncol., March 20, 2009; 27(9): 1456 - 1461. [Abstract] [Full Text] [PDF] N. G. Schaefer, C. Taverna, K. Strobel, C. Wastl, M. Kurrer, and T. F. Hany Hodgkin Disease: Diagnostic Value of FDG PET/CT after First-Line Therapy--Is Biopsy of FDG-avid Lesions Still Needed? Radiology, July 1, 2007; 244(1): 257 - 262. [Abstract] [Full Text] [PDF] A. Evens, J. Altman, B. Mittal, N Hou, A Rademaker, D Patton, L Kaminer, S Williams, S Duffey, D Variakojis, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma Ann. Onc., April 1, 2007; 18(4): 679 - 688. [Abstract] [Full Text] [PDF] E. Brusamolino and A. M. Carella Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives Haematologica, January 1, 2007; 92(1): 6 - 10. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020